Babson’s David Stein: “Succeeding where Theranos failed”
Listen now
Description
The Sunday Times’ tech correspondent Danny Fortson brings on David Stein, chief executive of Babson Diagnostics, to talk about the importance of blood testing (4:49), why Babson is not Theranos (6:47), trying to compete with that idea (9:26), why they succeeded where Theranos failed (14:34), using a tiny amount of blood (18:23), fighting against the Theranos effect (24:37), being owned by a company they aim to disrupt (26:28), liquid biopsies (28:02), the new age of biological data (32:23), regulatory approval (37:09), and avoiding the spotlight (39:03).
Hosted on Acast. See acast.com/privacy for more information.
More Episodes
The Sunday Times’s tech correspondent Danny Fortson brings on Augustus Doricko to talk about becoming a Thiel fellow (3:15), looking for the proof of God (5:45), starting his first company (9:30) cloud seeding (11:30), the history of cloud seeding (13:30), on whether silver iodide is safe...
Published 04/26/24
The Sunday Times’ tech correspondent Danny Fortson brings on DoNotPay's Josh Browder to talk about how artificial intelligence is changing his business (4:20), paying a dividend (8:15), blowing up the myth that you have to lose money to get big (11:00), the coming AI crash (13:00), the path...
Published 04/19/24
Published 04/19/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
